Trk receptor

Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades.The common ligands of trk receptors are neurotrophins, a family of growth factors critical to the functioning of the nervous system. The binding of these molecules is highly specific. Each type of neurotrophin has different binding affinity toward its corresponding Trk receptor. The activation of Trk receptors by neurotrophin binding may lead to activation of signal cascades resulting in promoting survival and other functional regulation of cells.

Cat. No.	Product name	CAS No.	Purity
T13208	TrkA-IN-1	1680179-43-4	98%
T13208	TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.
T14363	AZ-23	915720-21-7	98%
T14363	AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C. For TrkA, TrkB, FGFR1, Flt3, Ret, MuSk, Lck, the IC50s values are 2 nM, 8 nM, 24 nM, 52 nM, 55 nM,...
T17000	Tavilermide	263251-78-1	98%
T17000	Tavilermide is a selective and partial agonist of TrkA or a nerve growth factor mimetic.
T9496	LOXO-195	1350884-56-8	98%
T9496	(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
T13207	PF-06733804	1873373-33-1	98%
T13207	PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.
T17169	Trk-IN-4	1799788-94-5	98%
T17169	Trk-IN-4 is an effective pan-Trk inhibitor in cell-based assays (IC50s: 1.9 nM, 2.6 nM, and 1.1 nM for TrkA, TrkB, and TrkC, respectively).
TN2890	3,5,7,15-Tetraacetoxy-9-nicotinoyloxy-6(17),11-jatrophadien-14-one	244277-75-6	98%
TN2890	Standard reference
T17170	PF-06737007	1863905-38-7	98%
T17170	PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively).
T9292	ALE-0540	234779-34-1	98%
T9292	ALE-0540 is a nonpeptidic heterocyclic molecule that inhibits the binding of NGF to p75 and TrkA, as well as signal transduction and biological responses mediate...
T2349	BMS-754807	1001350-96-4	98%
T2349	Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
T5995	Larotrectinib	1223403-58-4	100%
T5995	Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
T5635	CH7057288	2095616-82-1	98%
T5635	CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.
T1704	Diosmetin	520-34-3	98%
T1704	Diosmetin has been found to act as a weak TrkB receptor agonist.
T7568	LM22A-4	37988-18-4	98%
T7568	LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 : 47 nM in a fluorescence anis...
T6712	Tyrphostin AG 879	148741-30-4	98%
T6712	Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.
T8327	ONO-7475	1646839-59-9	98.33%
T8327	ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase
T2816	7,8-Dihydroxyflavone	38183-03-8	98.37%
T2816	7, 8-Dihydroxyflavone (7, 8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.
T2094	Danusertib	827318-97-8	98.44%
T2094	Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
T14921	CE-245677	717899-97-3	98.99%
T14921	CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.
T4496	LM22B-10	342777-54-2	99.13%
T4496	LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.